This book is a very useful reference guide on how de jure and de facto standards are being developed and how these standards compete against each other. The book also looks at how FRAND commitments are being determined across countries, how these disputes have played out, especially in Asia, and how they can be better dealt with in future globally. The book gives a broad overview of the business model of dominant SEP patentees and analyzes some standards for FRAND licensing of SEPs which are converging in major Asian jurisdictions. It highlights the need for ex ante regulation in the FRAND licensing of SEPs and suggests how we can reconcile conflicts which may arise from different legal standards. This book provides detailed and comprehensive analysis of recent SEP cases with an emphasis on Asia and will interest anyone who wishes to have more insight into the legal, policy, industrial and economic implications of such issues.

This open access book is the outcome of a Global Forum on Innovation, Intellectual Property and Access to Medicines held in December 2019 at the Max Plank Instititute in Munich, organised by the South Centre and the Max Plank Institute. The academics and experts from international organisations participating have contributed chapters to this book. The book is for policy makers (in Ministries of Health, Ministries of Trade, Ministries of Foreign Affairs, patent offices), but also relevant for academics (law, trade, public health), on the flexibilities available in the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization to promote access to medicines.

This book is a very useful reference guide on how de jure and de facto standards are being developed and how these standards compete against each other. The book also looks at how FRAND commitments are being determined across countries, how these disputes have played out, especially in Asia, and how they can be better dealt with in future globally. The book gives a broad overview of the business model of dominant SEP patentees and analyzes some standards for FRAND licensing of SEPs which are converging in major Asian jurisdictions. It highlights the need for ex ante regulation in the FRAND licensing of SEPs and suggests how we can reconcile conflicts which may arise from different legal standards. This book provides detailed and comprehensive analysis of recent SEP cases with an emphasis on Asia and will interest anyone who wishes to have more insight into the legal, policy, industrial and economic implications of such issues.

This open access book is the outcome of a Global Forum on Innovation, Intellectual Property and Access to Medicines held in December 2019 at the Max Plank Instititute in Munich, organised by the South Centre and the Max Plank Institute. The academics and experts from international organisations participating have contributed chapters to this book. The book is for policy makers (in Ministries of Health, Ministries of Trade, Ministries of Foreign Affairs, patent offices), but also relevant for academics (law, trade, public health), on the flexibilities available in the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization to promote access to medicines.

Im Zuge der Finanz- und Wirtschaftskrise wird verstarkt diskutiert, welcher Mechanismen es bedarf, um die Interessen "aller "Marktteilnehmer im Wirtschaftsleben zu wahren. Grosse Bedeutung gewonnen hat dabei der Aspekt der " business ethics ." So richten immer mehr Unternehmen sog. Compliance-Abteilungen ein, die die Einhaltung von unternehmensinternen Grundsatzen wie namentlich die der " Corporate Social Responsibility "(CSR) zur Aufgabe haben. Kaum untersucht ist bislang jedoch die "rechtliche Verbindlichkeit "solcher CSR-Standards, obgleich sie zunehmend von Unternehmen auf ihrer Website verkundet oder auf anderem Wege zu Public Relations- und Marketingzwecken bis hin zur Werbung eingesetzt werden.

Sind CRS damit nur wohlklingende Absichtserklarungen, oder handelt es sich um rechtlich verbindliche Standards und wenn ja, unter welchen Voraussetzungen entsteht ein Rechtsanspruch gegen Unternehmungen, wenn diese die sich selbst gegebenen Standards nicht einhalten? Anders gefragt: Gibt es ein corporate right to lie, oder setzt das (deutsche, europaische, internationale) Recht Grenzen? Im Fokus steht hierbei das "Recht zur ""Bekampfung unlauteren Wettbewerbs," im deutschen Sprachgebrauch kurz auch Lauterkeitsrecht genannt, das in allen entwickelten Wirtschaftsnationen wenn auch mit unterschiedlichem Ansatz Markthandlungen unter dem Gesichtspunkt der Fairness uberpruft.

Die Autoren der Beitrage dieses Buches sind ausgewiesene Fachleute des Europa-, Wirtschafts- und Wettbewerbsrechts. Sie diskutieren auf der Grundlage rechtstatsachlicher Erkenntnisse alle mit der wettbewerbsrechtlichen Beurteilung von CSR zusammenhangenden Fragen, insbesondere unter Berucksichtigung der Rolle, die CSR fur Unternehmen, Abnehmer und die Gesamtwirtschaft spielt.

Auch die Vorstellungen anderer Rechtsordnungen und Kulturkreise sind einbezogen. Gefragt wird letztlich, ob es ein U"nternehmerleitbild "gibt, das die Beachtung ethischer Standards einschliesst und das uber das Lauterkeitsrecht auch rechtliche Verbindlichkeit erlangt.

Mit Keynote von "Gesine Schwan."

"

This book examines the impact and shortcomings of the TRIPS Agreement, which was signed in Marrakesh on 15 April 1994. Over the last 20 years, the framework conditions have changed fundamentally. New technologies have emerged, markets have expanded beyond national borders, some developing states have become global players, the terms of international competition have changed, and the intellectual property system faces increasing friction with public policies. The contributions to this book inquire into whether the TRIPS Agreement should still be seen only as part of an international trade regulation, or whether it needs to be understood - or even reconceptualized - as a framework regulation for the international protection of intellectual property. The purpose, therefore, is not to define the terms of an outright revision of the TRIPS Agreement but rather to discuss the framework conditions for an interpretative evolution that could make the Agreement better suited to the expectations and needs of today's global economy.